Hanmi Pharm has decided to change the development direction for its GLP-1 class drug ‘efpeglenatide.’ Instead of developing it as a diabetes treatment as before, the company plans to develop the drug as an obesity treatment.

The industry’s attention was focused on the Global Phase III trial that Sanofi and Hanmi Pharm had conducted with efpeglenatide as a diabetes treatment. The results of the trial, 'AMPLITUDE-M,’ had indirectly confirmed the weight loss effect of efpeglenatide.

In the trial, the weight of patients in the U.S. and Europe with diabetes who received 4mg efpeglenatide fell by 3.34kg on average. However, it would be difficult to rashly assume the results as the race or